The use of protease inhibitors (PIs) in the antiretroviral therapy (ART) of HIV-1 infection has reduced the rate of morbidity and mortality; but, unfortunately, this therapy has several side effects and a long term toxicity. Unexpected lipid abnormalities and cardiovascular complications are observed. We report a case of myocardial infarction in a young man HIV-1 positive patient without a history of metabolic disorders and cardiovascular pathologies undergoing PI treatment. The new ART without PI was not suppressive, while hypertriglyceridemia value improved by omega 3 fatty acids use. Our opinion is to continue ART with PI and to correct lipid abnormalities with the use of antidislipidemic drugs instead to change a demonstrated suppressive ART.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Updates to HIV transmission rate estimates along the HIV care continuum in the United States, 2019.
J Acquir Immune Defic Syndr
January 2025
Division of HIV Prevention, Centers for Disease Control and Prevention, Atlanta, GA, US at the time this research was undertaken. Current affiliation: Manhattan Associates, Atlanta GA.
Background: In 2019, there were an estimated 1.2 million persons with HIV (PWH) and 35,100 new infections in the United States. The HIV care continuum has a large influence on transmission dynamics.
View Article and Find Full Text PDFResearch progress of femoral head necrosis in HIV-infected patients.
Ann Med
December 2025
Department of Joint and Sports Medicine, Zhongnan Hospital, Wuhan University, Wuhan, China.
As life expectancy among patients infected with the human immunodeficiency virus (HIV) increases, a growing number of complications have been observed. This population displays an elevated risk of ischemic necrosis of the femoral head in comparison to the general population, which may be attributed to HIV infection, antiretroviral medication use, and hormone application. Patients infected with the human immunodeficiency virus (HIV) who also have necrosis of the femoral head tend to present at an earlier age, with a rapid disease progression and a high incidence of bilateral onset.
View Article and Find Full Text PDFAnti-HIV-1 Effect of the Fluoroquinolone Enoxacin and Modulation of Pro-Viral hsa-miR-132 Processing in CEM-SS Cells.
Noncoding RNA
January 2025
Institute of Pharmaceutical Sciences, ETH Zurich, 8093 Zurich, Switzerland.
Background: Despite tremendous advances in antiretroviral therapy (ART) against HIV-1 infections, no cure or vaccination is available. Therefore, discovering novel therapeutic strategies remains an urgent need. In that sense, miRNAs and miRNA therapeutics have moved intensively into the focus of recent HIV-1-related investigations.
View Article and Find Full Text PDFDeterminants of Familiarity and Experience with HIV Pre-Exposure Prophylaxis in Primary Care Providers in Ontario, Canada.
J Prim Care Community Health
January 2025
Division of Infectious Diseases, Department of Medicine, Queen's University, Kingston, Canada.
Background: Despite increased access to HIV pre-exposure prophylaxis (PrEP) in Canada, familiarity and experience among primary care providers (PCPs)-including family doctors and those working with key populations-remains limited. To understand the barriers and facilitators of PrEP familiarity and experience, we conducted a situational analysis in PCPs in sub-urban and rural Ontario.
Methods: We surveyed a non-probabilistic sample of PCPs using an online questionnaire, designed with the Consolidated Framework for Implementation Research (CFIR).
A global review of national guidelines of post-exposure prophylaxis for the prevention of HIV.
J Int AIDS Soc
January 2025
Melbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.
Introduction: The World Health Organization (WHO) recommends the use of antiretroviral drugs as post-exposure prophylaxis (PEP) for preventing HIV acquisition for occupational and non-occupational exposures. To inform the development of global WHO recommendations on PEP, we reviewed national guidelines of PEP for their recommendations.
Methods: Policies addressing PEP from 38 WHO HIV priority countries were obtained by searching governmental and non-governmental websites and consulting country and regional experts; these countries were selected based on HIV burden, new HIV acquisitions and the number of HIV-associated deaths.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!